Zobrazeno 1 - 10
of 1 010
pro vyhledávání: '"Bolger MB"'
Autor:
Le Merdy M; Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA., Szeto KX; Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA., Perrier J; PhinC Development, 36 Rue Victor Basch, 91300 Massy, France., Bolger MB; Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA., Lukacova V; Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2024 Jan 10; Vol. 16 (1). Date of Electronic Publication: 2024 Jan 10.
Autor:
Bolger MB; Simulations Plus, Inc., 42505 10(th) Street West, Lancaster, CA 93534, USA. Electronic address: michael.bolger@simulations-plus.com.
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2022 Dec; Vol. 352, pp. 833-839. Date of Electronic Publication: 2022 Nov 11.
Autor:
García MA; Johannes Gutenberg-Universität, Staudingerweg 5, 55099 Mainz, Germany., Bolger MB; Simulations Plus, Inc., 42505 10th St. West, Lancaster, CA, United States., Suarez-Sharp S; Simulations Plus, Inc., 42505 10th St. West, Lancaster, CA, United States., Langguth P; Johannes Gutenberg-Universität, Staudingerweg 5, 55099 Mainz, Germany. Electronic address: langguth@uni-mainz.de.
Publikováno v:
Journal of pharmaceutical sciences [J Pharm Sci] 2022 Jan; Vol. 111 (1), pp. 262-273. Date of Electronic Publication: 2021 Oct 20.
Autor:
Reddy MB; Early Clinical Development, Department of Clinical Pharmacology Oncology, Pfizer, Boulder, CO 80301, USA., Bolger MB; Simulations Plus Inc., Lancaster, CA 93534, USA., Fraczkiewicz G; Simulations Plus Inc., Lancaster, CA 93534, USA., Del Frari L; PKPD Department, Pierre Fabre Laboratories, 31100 Toulouse, France., Luo L; Material & Analytical Sciences, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877, USA., Lukacova V; Simulations Plus Inc., Lancaster, CA 93534, USA., Mitra A; Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, Springhouse, PA 19477, USA., Macwan JS; Simulations Plus Inc., Lancaster, CA 93534, USA., Mullin JM; Simulations Plus Inc., Lancaster, CA 93534, USA., Parrott N; Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland., Heikkinen AT; Admescope Ltd., Fi-90620 Oulu, Finland.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2021 Aug 24; Vol. 13 (9). Date of Electronic Publication: 2021 Aug 24.
Autor:
Szeto KX; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA., Le Merdy M; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA., Dupont B; PhinC Development, 36 Rue Victor Basch, 91300, Massy, France., Bolger MB; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA., Lukacova V; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA. viera@simulations-plus.com.
Publikováno v:
The AAPS journal [AAPS J] 2021 Jun 24; Vol. 23 (4), pp. 89. Date of Electronic Publication: 2021 Jun 24.
Autor:
Cole, Susan1 (AUTHOR) susan.cole@mhra.gov.uk, Malamatari, Maria1 (AUTHOR), Butler, Andrew1 (AUTHOR), Arshad, Mahnoor2 (AUTHOR), Kerwash, Essam1 (AUTHOR)
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. Nov2024, Vol. 13 Issue 11, p1990-2001. 12p.
Autor:
Pettarin M; Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany., Bolger MB; Simulations Plus, Inc., Lancaster, CA 93534, United States., Chronowska M; Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany., Kostewicz ES; Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany. Electronic address: Kostewicz@em.uni-frankfurt.de.
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2020 Dec 01; Vol. 155, pp. 105552. Date of Electronic Publication: 2020 Sep 13.
Autor:
Le Merdy M; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA. maxime@simulations-plus.com., Spires J; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA., Lukacova V; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA., Tan ML; Food and Drug Administration, CDER/OGD/ORS/DQMM, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA., Babiskin A; Food and Drug Administration, CDER/OGD/ORS/DQMM, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA., Xu X; Food and Drug Administration, CDER/OPQ/OTR/DPQR, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA., Zhao L; Food and Drug Administration, CDER/OGD/ORS/DQMM, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA., Bolger MB; Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA.
Publikováno v:
Pharmaceutical research [Pharm Res] 2020 Nov 19; Vol. 37 (12), pp. 245. Date of Electronic Publication: 2020 Nov 19.
Autor:
Ahmad A; University of Manchester, United Kingdom. Electronic address: amais.ahmed@manchester.ac.uk., Pepin X; AstraZeneca, United Kingdom., Aarons L; University of Manchester, United Kingdom., Wang Y; University of Manchester, United Kingdom., Darwich AS; Royal Institute of Technology, Stockholm, Sweden., Wood JM; AstraZeneca, United Kingdom., Tannergren C; AstraZeneca, United Kingdom., Karlsson E; AstraZeneca, United Kingdom., Patterson C; AstraZeneca, United Kingdom., Thörn H; AstraZeneca, United Kingdom., Ruston L; AstraZeneca, United Kingdom., Mattinson A; AstraZeneca, United Kingdom., Carlert S; AstraZeneca, United Kingdom., Berg S; AstraZeneca, United Kingdom., Murphy D; AstraZeneca, United Kingdom., Engman H; AstraZeneca, United Kingdom., Laru J; AstraZeneca, United Kingdom., Barker R; AstraZeneca, United Kingdom., Flanagan T; AstraZeneca, United Kingdom., Abrahamsson B; AstraZeneca, United Kingdom., Budhdeo S; AstraZeneca, United Kingdom., Franek F; AstraZeneca, United Kingdom., Moir A; AstraZeneca, United Kingdom., Hanisch G; AstraZeneca, United Kingdom., Pathak SM; Certara, Simcyp Division, United Kingdom., Turner D; Certara, Simcyp Division, United Kingdom., Jamei M; Certara, Simcyp Division, United Kingdom., Brown J; Bristol-Myers Squibb, United Kingdom., Good D; Bristol-Myers Squibb, United Kingdom., Vaidhyanathan S; Bristol-Myers Squibb, United Kingdom., Jackson C; Bristol-Myers Squibb, United Kingdom., Nicolas O; Sanofi, United States., Beilles S; Sanofi, United States., Nguefack JF; Sanofi, United States., Louit G; Sanofi, United States., Henrion L; Sanofi, United States., Ollier C; Sanofi, United States., Boulu L; Sanofi, United States., Xu C; Sanofi, United States., Heimbach T; Novartis, United States., Ren X; Novartis, United States., Lin W; Novartis, United States., Nguyen-Trung AT; Novartis, United States., Zhang J; Novartis, United States., He H; Novartis, United States., Wu F; Novartis, United States., Bolger MB; Simulation Plus, Inc., United States., Mullin JM; Simulation Plus, Inc., United States., van Osdol B; Simulation Plus, Inc., United States., Szeto K; Simulation Plus, Inc., United States., Korjamo T; Orion Pharma, Finland., Pappinen S; Orion Pharma, Finland., Tuunainen J; Orion Pharma, Finland., Zhu W; Merck Research Laboratories, Merck & Co., United States., Xia B; Merck Research Laboratories, Merck & Co., United States., Daublain P; Merck Research Laboratories, Merck & Co., United States., Wong S; Pfizer, United States., Varma MVS; Pfizer, United States., Modi S; Pfizer, United States., Schäfer KJ; Boehringer-ingelheim, Germany., Schmid K; Boehringer-ingelheim, Germany., Lloyd R; GlaxoSmithKline, United Kingdom., Patel A; GlaxoSmithKline, United Kingdom., Tistaert C; Janssen, Belgium., Bevernage J; Janssen, Belgium., Nguyen MA; Johannes Gutenberg University of Mainz, Germany., Lindley D; AbbVie, Germany., Carr R; AbbVie, Germany., Rostami-Hodjegan A; University of Manchester, United Kingdom; Certara, Simcyp Division, United Kingdom.
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2020 Nov; Vol. 156, pp. 50-63. Date of Electronic Publication: 2020 Aug 14.
Autor:
Jamei M; Certara UK Limited (Simcyp Division), Sheffield, UK. Electronic address: masoud.jamei@certara.com., Abrahamsson B; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden., Brown J; Bristol-Myers Squibb, Reeds Lane, Moreton, Wirral CH46 1QW, UK., Bevernage J; Janssen Research & Development, Small Molecules Pharmaceutical Development, Biopharmaceutics, Beerse, Belgium., Bolger MB; Simulations Plus, Inc., Lancaster, CA, USA., Heimbach T; Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, NJ, USA., Karlsson E; Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden., Kotzagiorgis E; European Medicines Agency, Amsterdam, the Netherlands., Lindahl A; Swedish Medical Products Agency, Uppsala, Sweden., McAllister M; Pfizer Global Research & Development, Sandwich, UK., Mullin JM; Simulations Plus, Inc., Lancaster, CA, USA., Pepin X; New Modalities & Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK., Tistaert C; Janssen Research & Development, Small Molecules Pharmaceutical Development, Biopharmaceutics, Beerse, Belgium., Turner DB; Certara UK Limited (Simcyp Division), Sheffield, UK., Kesisoglou F; Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, NJ, USA.
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2020 Oct; Vol. 155, pp. 55-68. Date of Electronic Publication: 2020 Aug 08.